ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Xiaomi Shares Jump on Europe EV Expansion Plan 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
OpenAI Rejects Apple Trade Secret Theft Claims 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Add as a preferred source on Google
HOPKINTON, Mass., March 09, 2018 -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin J. Driscoll, chairman, president, and chief executive officer of Spring Bank, will present at the upcoming Cowen and Company 38th Annual Health Care Conference, taking place March 12-14 at the Boston Marriott Copley Place hotel in Boston, Massachusetts.
| Cowen and Company 38th Annual Health Care Conference | ||
| Date: | Wednesday, March 14 | |
| Time: | 9:20am Eastern Time | |
About Spring Bank
Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its most advanced SMNH product candidate, inarigivir, for the treatment of viral diseases, including hepatitis B virus (HBV) and other SMNH product candidates, including SB 11285, the company’s lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of INterferon Genes, or STING, pathway.
Contacts
For investor inquires:
Spring Bank Pharmaceuticals, Inc.
Jonathan Freve
Chief Financial Officer
(508) 473-5993
LifeSci Advisors, LLC
Andrew McDonald
(646) 597-6987
[email protected]
Media contact:
Josephine Belluardo, Ph.D.
LifeSci Public Relations
(646) 751-4361
[email protected]
